Prime Medicine (PRME) Reports Q1 EPS
Prime Medicine, Inc. (NASDAQ:PRME) reported its Q1 2026 earnings, with an EPS of (28c) against a consensus of (25c), and revenue of $856,000. CEO Allan Reine highlighted the company's progress in advancing Prime Editing technology, with regulatory filings expected for PM577 and PM647, and initial data anticipated in 2027. The company also announced the appointment of Svetlana Makhni as Chief Financial Officer to oversee financial operations.
Prime Medicine (PRME) Reports Q1 EPS
Prime Medicine (PRME) reported its Q1 earnings per share of (28c), missing the consensus estimate of (25c), but revenue of $856,000 exceeded expectations. The company is advancing its Prime Editing technology pipeline, with regulatory applications for PM577 and PM647 expected in the first half and mid-year respectively, and initial data anticipated in 2027. Prime Medicine also recently appointed Svetlana Makhni as Chief Financial Officer to oversee its financial operations.
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Hold Rating
H.C. Wainwright has reiterated its Hold rating on Prime Medicine (PRME.US). This indicates that the firm advises investors to maintain their current positions in the company's stock, suggesting a neutral outlook on its near-term performance.
Prime Medicine (NasdaqGM:PRME) Stock Forecast & Analyst Predictions
Prime Medicine (NasdaqGM:PRME) is forecast to experience declining earnings but significant revenue growth, with analysts predicting a future net loss per share but a higher price target. The company recently appointed new executives and initiated several follow-on equity offerings, while strategically prioritizing its in vivo liver franchise for Wilson's Disease and Alpha-1 Antitrypsin Deficiency. Despite high cash burn and stock volatility, Prime Medicine continues to advance its gene-editing pipeline with promising preclinical data and strategic partnerships.
Prime Medicine, Inc. (PRME) reports Q1 loss, misses revenue estimates
Prime Medicine, Inc. (PRME) reported a Q1 loss, missing revenue estimates. The company's financial performance for the first quarter did not meet analysts' expectations.
Prime Medicine (Nasdaq: PRME) Q1 2026 results, cash runway into 2027 and pipeline update
Prime Medicine reported its Q1 2026 financial results, with a narrower net loss of $49.1 million and collaboration revenue of $0.9 million. The company announced a cash runway extending into 2027 and provided updates on its gene-editing pipeline, including planned regulatory filings for PM577 and PM647 in 2026 and continued dialogue for PM359. Additionally, Svetlana Makhni was appointed as Chief Financial Officer.
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine, Inc. reported its first-quarter 2026 financial results, highlighting progress in its Prime Editing platform. The company is on track to file regulatory applications for PM577 in Wilson Disease and PM647 in AATD in mid-2026, with initial clinical data expected in 2027. Additionally, Prime Medicine continues regulatory dialogue for a potential Biologics License Application (BLA) for PM359 in Chronic Granulomatous Disease (CGD) and announced a cash runway into 2027 based on its current financial position.
Prime Medicine targets 2 liver disease filings in 2026, data due 2027
Prime Medicine reported Q1 2026 financial results, including a net loss of $49.1 million and a cash position of $149.2 million providing runway into 2027. The company is on track to file IND/CTA applications for its Wilson Disease (PM577) and AATD (PM647) programs in 2026, with initial clinical data from both expected in 2027. Additionally, Prime Medicine continues regulatory dialogue for a potential Biologics License Application (BLA) for PM359 in Chronic Granulomatous Disease (CGD).
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine, Inc. announced its Q1 2026 financial results, reporting a net loss of $49.1 million and cash reserves of $149.2 million, providing a runway into 2027. The company is on track to file IND/CTA applications for PM577 (Wilson Disease) in H1 2026 and PM647 (AATD) by mid-2026, with initial clinical data expected in 2027. Prime Medicine also continues regulatory dialogue with the FDA for a BLA filing for PM359 in Chronic Granulomatous Disease (CGD) and recently appointed Svetlana Makhni as CFO.
PRME SEC Filings - Prime Medicine 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Prime Medicine (Ticker: PRME) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It details the types of information found in these regulatory documents, such as financial results, material events, and governance matters. The platform offers AI-powered summaries and analysis to help investors quickly understand key points from the filings.
Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen
Wall Street Zen has upgraded Prime Medicine (NASDAQ:PRME) from a "strong sell" to a "sell" rating. Despite this, the stock holds a consensus "Moderate Buy" rating among analysts with a target price of $7.38. Prime Medicine, a biotechnology company developing Prime Editing technology, maintains significant institutional ownership and has shown a 52-week trading range of $1.11 to $6.94.
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) reported a third-quarter loss of $0.62 per share, which is wider than the Zacks Consensus Estimate of a $0.57 loss per share. The company's revenues for the quarter were $0.65 million, falling short of analyst estimates and representing a significant decline compared to the previous year. This weaker-than-expected financial performance led to a slight dip in the company's stock price after the earnings announcement.
[ARS] Prime Medicine, Inc. SEC Filing
This article reports on an ARS SEC filing by Prime Medicine, Inc. (PRME) on April 23, 2026, which is available as a PDF document. The filing has a low impact and neutral sentiment. The article also provides a company overview, including market cap, industry, and recent news and SEC filings for Prime Medicine.
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) reported a significant loss per share and missed revenue estimates in its Q2 earnings report. The company's net loss was $0.78 per share, compared to analyst expectations of a $0.46 loss, while revenue of $0.94 million fell short of the $1.7 million consensus. This performance led to a notable positive stock movement, but the company's financial results were largely driven by non-operating income from an investment.
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Rating of "Moderate Buy" by Brokerages
Prime Medicine, Inc. (NASDAQ:PRME) has received a consensus "Moderate Buy" rating from nine brokerages, with an average 12-month price target of $7.375. Institutional ownership stands at 70.37%, with several firms increasing their stakes recently. The biotechnology company, specializing in Prime Editing technology, currently has a market capitalization of $668.04 million and trades with a negative P/E ratio.
PRME Price Today: Prime Medicine, Inc. Stock Price, Quote & Chart | MEXC
This article provides the current stock price and financial data for Prime Medicine, Inc. (PRME), trading at $3.67 with a -0.95% change. It details the company's market performance, including short-term and 12-month returns, and offers instructions on how to buy PRME stock on MEXC. The article also describes Prime Medicine, Inc. as a biotechnology company developing genetic medicines and includes a comprehensive FAQ section about its financials and industry classification.
Prime Medicine (NASDAQ: PRME) details 2026 meeting, board elections and pay
Prime Medicine will hold its 2026 virtual annual shareholder meeting on June 5, 2026, to elect two Class I directors, Michael Kelly and David Schenkein, M.D., and ratify PricewaterhouseCoopers LLP as its independent auditor. The proxy statement details director independence, committee compositions, updated non-employee director compensation, and 2025 executive pay, including salaries, bonuses, and stock option grants. Shareholders of record as of April 9, 2026, are eligible to vote.
Sumitomo Mitsui Trust Group Inc. Sells 384,418 Shares of Prime Medicine, Inc. $PRME
Sumitomo Mitsui Trust Group Inc. reduced its stake in Prime Medicine, Inc. by 10.6% during the fourth quarter, selling 384,418 shares. The firm now holds 3,245,506 shares of Prime Medicine, valued at approximately $11.26 million, representing 1.80% of the company. Prime Medicine shares opened at $3.81, with a market cap of $687.90 million, and currently hold a "Moderate Buy" consensus rating from analysts with an average price target of $7.38.
Prime Medicine (PRME) CFO Makhni Svetlana Ni submits initial Form 3
Prime Medicine, Inc.'s Chief Financial Officer, Makhni Svetlana Ni, has filed an initial Form 3 with the SEC. This filing officially establishes her as a reporting person under SEC rules. The Form 3 details her position as CFO but does not report any current stock transactions or beneficial ownership of securities at the time of the filing.
Prime Medicine (PRME) awards CFO 800,000 stock options at $3.67
Prime Medicine, Inc. (PRME) has awarded its Chief Financial Officer, Svetlana Ni Makhni, 800,000 stock options with an exercise price of $3.67 per share, expiring on April 16, 2036. The options will vest over time, with 25% on April 16, 2027, and the remainder vesting monthly over the subsequent 36 months, contingent on her continued service. This grant is a compensation-related award rather than an open-market transaction.
Prime Medicine appoints Svetlana Makhni as CFO
Prime Medicine, Inc. (NASDAQ:PRME) has appointed Svetlana Makhni as its new Chief Financial Officer. Makhni brings over 20 years of experience in biotechnology and healthcare finance, having previously served as CFO of Marengo Therapeutics and held investment banking roles. Her appointment comes as Prime Medicine, a biotechnology company with a $671 million valuation and strong financial health, prepares for clinical trials for Wilson Disease and Alpha-1 Antitrypsin Deficiency treatments, despite its stock experiencing volatility.
Prime Medicine appoints Svetlana Makhni as chief financial officer
Prime Medicine has appointed Svetlana Makhni as Chief Financial Officer, effective immediately. Ms. Makhni brings over 20 years of experience in biotechnology and healthcare finance, and her compensation package includes an annual base salary, sign-on bonus, equity, and severance provisions. Her appointment comes as Prime Medicine's stock has seen significant returns, although it is characterized by high volatility.
Prime Medicine names Svetlana Makhni as chief financial officer
Prime Medicine has appointed Svetlana Makhni as its new Chief Financial Officer. Makhni, with over 20 years of experience in biotech and healthcare finance, will oversee financial operations and strategy as the company prepares for clinical trials for Wilson Disease and Alpha-1 Antitrypsin Deficiency treatments. Despite negative free cash flow, the company's stock has surged, and its liquid assets exceed short-term obligations, providing financial flexibility.
Prime Medicine Appoints Svetlana Makhni as New CFO
Prime Medicine, Inc. announced the appointment of Svetlana Makhni as Chief Financial Officer and principal financial officer, effective April 16, 2026. Makhni, a veteran in biotechnology and healthcare finance, will receive a comprehensive employment package including salary, bonus eligibility, severance protections, and stock options. Current CEO Allan Reine will transition out of the principal financial officer role to focus on his chief executive duties, signaling a clearer separation of financial and operational leadership.
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Prime Medicine has appointed Svetlana Makhni as its new Chief Financial Officer, where she will manage financial operations, investor relations, and corporate development. Ms. Makhni brings over 20 years of experience in biotechnology and healthcare finance, previously serving as CFO for Marengo Therapeutics and Escient Pharmaceuticals. Her appointment is expected to be instrumental as Prime Medicine prepares to initiate clinical trials for Wilson Disease and Alpha-1 Antitrypsin Deficiency.
Prime Medicine Names Svetlana Makhni CFO Ahead of Planned Clinical Progress
Prime Medicine has appointed Svetlana Makhni as its new Chief Financial Officer, bringing extensive experience in biotech finance, capital markets, and dealmaking. This strategic hire positions the gene-editing company for its upcoming clinical advancements in Wilson disease and Alpha-1 Antitrypsin Deficiency. Makhni's role will be crucial in managing finance, investor relations, and corporate development as the company moves into a more execution-focused phase.
CFO package at Prime Medicine (NASDAQ: PRME) details pay, options and severance
Prime Medicine (NASDAQ: PRME) has appointed Svetlana Makhni as Chief Financial Officer, effective April 16, 2026. Her compensation package includes a $495,000 annual base salary, a $40,000 sign-on bonus, and eligibility for an annual bonus targeted at 40% of her base salary, along with significant stock options. The company also detailed standard severance protections and enhanced benefits in case of a change in control, formalizing the separation of finance and CEO roles.
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Prime Medicine, Inc. has announced the appointment of Svetlana Makhni as its new Chief Financial Officer. Ms. Makhni will lead the company's financial operations and strategy, bringing over 20 years of experience in biotechnology and healthcare finance. Her expertise is expected to be instrumental as Prime Medicine prepares to advance its Wilson Disease and Alpha-1 Antitrypsin Deficiency programs into clinical trials.
Prime Medicine hires CFO as it prepares for two clinic entries
Prime Medicine (Nasdaq: PRME) has appointed Svetlana Makhni as Chief Financial Officer, effective April 16, 2026. She brings over 20 years of experience in biotech and investment banking. Her appointment is expected to strengthen financial leadership as the company prepares for clinical entry in Wilson Disease and Alpha-1 Antitrypsin Deficiency, along with advancing its broader Prime Editing programs.
Prime Medicine slides after pricing $125.4M stock offering
Prime Medicine's stock fell significantly after the company priced a public offering of 18.25 million shares at $6.87 per share, aiming to raise $125.4 million. The offering includes a 30-day option for underwriters to purchase an additional 2.7375 million shares. The stock's performance this year has been a gain of about 15%.
Prime Medicine (NASDAQ:PRME) Downgraded to "Strong Sell" Rating by Wall Street Zen
Wall Street Zen has downgraded Prime Medicine (NASDAQ:PRME) from a "sell" to a "strong sell" rating. Despite this, other analysts offer a "Moderate Buy" consensus with a target price of $7.38, while the stock currently trades around $3.43. The company, focused on gene editing technologies, has seen significant institutional investor activity in the last quarter.
Prime Medicine (NASDAQ:PRME) Trading Down 6.4% - Here's What Happened
Prime Medicine (NASDAQ:PRME) saw its stock price drop by 6.4% on Friday, trading at $3.285 on significantly lower-than-average volume. Despite the decline, analysts hold a "Moderate Buy" consensus rating with an average price target of $7.38, including recent "strong-buy" and "outperform" initiations. The company has a market capitalization of $607.6 million, with a substantial portion of its stock owned by institutional investors.
PRME PE Ratio & Valuation, Is PRME Overvalued
Prime Medicine Inc (PRME) is currently deemed "Undervalued" based on its forward PS ratio of 32.39 compared to its five-year average of -4.89, with a fair price estimated between $8.39 and $10.12 against its current price of $3.43. While its Price-to-Book ratio is higher than its 3 and 5-year averages, its P/S ratio of 31.57 is significantly below the competitor average of 288.07, raising concerns given its negative revenue growth. The analysis suggests that while PRME appears undervalued by some metrics, a deeper look into competitor valuations and revenue growth paints a more complex picture.
Citizens reiterates Prime Medicine stock rating on PM359 pathway
Citizens reiterated a "Market Outperform" rating and a $6.00 price target for Prime Medicine (NASDAQ:PRME) shares, despite the stock trading below the target at $4.23 and appearing overvalued. The re-rating is based on the potential regulatory pathway for PM359, which has shown proof-of-concept and may qualify under new FDA draft guidance, potentially requiring limited additional financial investment. Prime Medicine is also pursuing AATD and WD clinical trials this year, alongside managing its cash burn despite a strong balance sheet.
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
The regenerative medicine market is projected to reach $578 billion by 2033 but faces a significant manufacturing hurdle: scaling production of living therapeutics. While companies like Prime Medicine, Madrigal Pharmaceuticals, Iovance Biotherapeutics, and Denali Therapeutics are making progress, Avaí Bio, in a joint venture with Austrianova, has solved a critical foundational step by initiating the manufacturing of a Master Cell Bank for its α-Klotho protein therapy. This approach, combined with Austrianova's Cell-in-a-Box® encapsulation technology, aims to transform patient-specific treatments into scalable, off-the-shelf products.
Prime Medicine, Inc. (NASDAQ:PRME) Receives Consensus Rating of "Moderate Buy" from Brokerages
Prime Medicine, Inc. (NASDAQ:PRME) has received a "Moderate Buy" consensus rating from brokerages, with an average 1-year price target of $7.38 from nine analysts. Recent analyst activities include Oppenheimer initiating coverage with an "outperform" rating and a $11 target, and Lifesci Capital upgrading the stock to "strong-buy." The article also notes that institutions own approximately 70.37% of the stock, with significant inflows during the fourth quarter.
2026: The Pivotal Year for Prime Medicine's Clinical Ambitions
Prime Medicine is approaching a critical period in 2026, shifting its focus from initial clinical proof-of-concept to broader in-body application of its gene-editing technology. The company, financially stable into 2027 with Bristol Myers Squibb's support, plans to advance both ex vivo (PM359 for chronic granulomatous disease) and in vivo therapies. Key milestones for 2026 include regulatory filings for Wilson disease and Alpha-1 antitrypsin deficiency, which will validate its prime-editing platform against CRISPR-based competitors.
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3% - What's Next?
Prime Medicine (NASDAQ:PRME) saw its stock price drop by 7.3% on Friday, trading at an intraday low of $3.36 with significantly reduced trading volume. Despite this decline, analysts maintain a "Moderate Buy" consensus rating with an average target price of $7.38. Institutional investors, including Alphabet, ARK, State Street, Vanguard, and Farallon, have recently increased their stakes in the company, which has a market capitalization of approximately $607.6 million.
PRME Stock Price, Quote & Chart | PRIME MEDICINE INC (NASDAQ:PRME)
This article provides an overview of PRIME MEDICINE INC (NASDAQ:PRME) stock, highlighting its current price, performance metrics, and key statistics. It also includes technical and fundamental analysis ratings from ChartMill, recent earnings data, analyst forecasts, and company information. The article indicates that PRME is a biotechnology company focused on developing genetic therapies.
Prime Medicine, Inc. (PRME) reports Q4 loss, misses revenue estimates
The article reports that Prime Medicine, Inc. (PRME) announced a Q4 loss and missed revenue estimates. This financial performance is likely to be a key point of discussion for investors and analysts following the company.
Prime Medicine slips after Q4 updates
The article reports that Prime Medicine's stock slipped following its Q4 updates. Further details regarding the Q4 updates and reasons for the slip are unavailable as the content is currently "MSN".
Casdin Capital LLC Acquires 1,600,000 Shares of Prime Medicine, Inc. $PRME
Casdin Capital LLC significantly increased its stake in Prime Medicine, Inc. (NASDAQ:PRME) by 102.1% in Q3, purchasing an additional 1,600,000 shares to hold a total of 3,167,175 shares valued at $17.55 million. This investment makes Prime Medicine the 14th largest holding in Casdin's portfolio, representing 1.5% of its total assets. Despite a "Moderate Buy" consensus rating from analysts with a target price of $7.75, the stock currently trades around $3.65, showcasing varied analyst opinions and significant institutional ownership.
Prime Medicine (NYSE:PRME) Earns Outperform Rating from Analysts at Oppenheimer
Oppenheimer initiated coverage on Prime Medicine (NYSE:PRME) with an "Outperform" rating and an $11 price target, indicating a potential 187.21% upside. Lifesci Capital also started coverage with an "Outperform" rating and a $6 price target. The company currently holds a "Moderate Buy" consensus rating and a $7.75 consensus price target from analysts, with 70.37% of its stock owned by institutional investors.
Oppenheimer bullish on Prime Medicine, initiates with an Outperform
Oppenheimer has initiated coverage of Prime Medicine (PRME) with an Outperform rating and an $11 price target, citing the company's leading gene-editing approach and a strong pipeline including a potentially best-in-class AATD program. The firm believes Prime Medicine's prime editing technology, validated by early clinical data and a partnership with BMS, offers significant upside potential, estimating 100%-200% growth within 10-15 months based on peer valuations. Oppenheimer also suggests that the stock's high short interest is not reflective of its fundamental value.
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) announced its first-quarter 2024 financial results, reporting a loss of $0.62 per share. This figure represents a narrower loss than the Zacks Consensus Estimate of a $0.78 loss but is 26.53% wider than the loss reported in the prior-year quarter. The company also missed revenue estimates, reporting $0.85 million against an anticipated $1.5 million.
Prime Medicine (NASDAQ:PRME) Trading Down 6.3% - Here's What Happened
Prime Medicine (NASDAQ:PRME) saw its stock price drop by 6.3% during Wednesday's mid-day trading to $3.79, with trading volume significantly lower than its daily average. Analyst ratings are split, with Lifesci Capital upgrading it to a "strong-buy" while Weiss Ratings reiterated a "sell," resulting in a "Moderate Buy" consensus from MarketBeat. The biotechnology company, focused on Prime Editing technology, has a market cap of $681.6 million and a negative P/E ratio.
[EFFECT] Prime Medicine, Inc. SEC Filing
This article reports on an EFFECT SEC filing by Prime Medicine, Inc. (PRME), indicating a neutral impact and sentiment. The filing, with an effectiveness date of March 4, 2026, involves a Notice of Effectiveness for an Accession Number 0001894562-26-000009. The article provides details like the company's CIK, file number, and a link to the original filing.
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway
Prime Medicine (PRME) is focusing its efforts on its in vivo liver franchise, with a cash runway of $191.4 million extending into 2027. The company is advancing lead liver-focused programs in Wilson Disease and Alpha-1 Antitrypsin Deficiency, expecting initial clinical data in 2027, and is also pursuing accelerated FDA approval for its Chronic Granulomatous Disease/CGD program. Despite a net loss in 2025, Prime Medicine maintained stable R&D expenses by optimizing its workforce and prioritizing clinical milestones.
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway
Prime Medicine (PRME) is shifting its focus to its in vivo liver franchise, supported by a $191.4 million cash runway into 2027. Despite a net loss, the company is advancing lead programs for Wilson Disease and Alpha-1 Antitrypsin Deficiency, expecting initial clinical data in 2027. Prime Medicine is also pursuing accelerated FDA approval for its CGD candidate, PM359, following positive Phase 1/2 data.
Prime Medicine, Inc. $PRME Shares Acquired by ARK Investment Management LLC
ARK Investment Management LLC significantly increased its stake in Prime Medicine (NYSE:PRME) by 135.8% in Q3, acquiring an additional 3,155,182 shares to hold a total of 5,477,851 shares, valued at approximately $30.35 million. This boosted ARK's ownership to 4.07% of the company, which has a market cap of $743.7 million. Despite a recent 2.6% dip in share price to $4.12, institutional ownership of Prime Medicine remains high at 70.37%, and analysts currently maintain a "Moderate Buy" consensus with an average price target of $7.21.
